Autoimmune Response to IGF 2 mRNA‐Binding Protein 2 (IMP 2/p62) in Breast Cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to understand the autoimmune response and immunogenicity of a tumour‐associated antigen IMP 2/p62 in breast cancer. Autoantibody responses to IMP 2/p62 were evaluated by enzyme‐linked immunosorbent assay (ELISA), Western blotting and indirect immunofluorescence assay in sera from patients with breast cancer, benign breast tumour and normal human individuals. Immunohistochemistry (IHC) study with breast cancer tissues was also performed to analyse protein expression of IMP 2/p62. The results have demonstrated that IMP 2/p62 can induce a relatively higher frequency of autoantibody response in breast cancer (14.3%, 7/49) compared to patients with benign breast tumour (5.6%, 2/36) and normal individuals (2.2%, 1/44). The frequency of IMP 2/p62 expression in breast cancer tissues was significantly higher than that in normal tissues (P < 0.01). The data suggest that autoantibody against IMP 2/p62 may be a useful serum biomarker for early‐stage breast cancer screening and diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., & Nielsen, F. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1262 · Cited by 721
Research works printed but not linked: 15
- 10.3322/caac.21166 · DOI · Paper page
- 10.1002/mas.20356 · DOI
- 10.1172/JCI14451 · DOI · Paper page
- 10.1111/j.1600-065X.2008.00611.x · DOI · Paper page
- 10.1084/jem.187.8.1163 · DOI · Paper page
- 10.1006/clim.2001.5048 · DOI
- 10.1016/S0002-9440(10)61770-1 · DOI
- 10.1084/jem.189.7.1101 · DOI · Paper page
- 10.1038/sj.onc.1201110 · DOI · Paper page
- 10.1074/jbc.M500270200 · DOI · Paper page
- Himoto T, 2005, Significance of autoantibodies against insulin‐like growth factor II mRNA‐binding proteins in patients with hepatocellular carcinoma, Int J Oncol, 26, 311
- 10.1038/sj.onc.1204838 · DOI
- 10.1007/s00018-012-1186-z · DOI · Paper page
- 10.3233/CBM-2009-0119 · doi:10.3233/cbm-2009-0119
- 10.1007/s13277-014-2756-5 · DOI
Cited by
Xia, T., Dai, X., Sang, M., Zhang, X., Xu, F., Wu, J., Shi, L., Wei, J., & Ding, Q. (2024) · Advanced Science · doi:10.1002/advs.202305142 · Cited by 52
CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast
McMullen, E. R., Gonzalez, M. E., Skala, S. L., Tran, M., Thomas, D., Djomehri, S. I., Burman, B., Kidwell, K. M., & Kleer, C. G. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4960-2 · Cited by 31
Zhao, J., Wu, Y., Yue, Y., Chen, M., Xu, Y., Liu, X., Liu, X., Gao, X., Wang, H., Si, X., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14772 · Cited by 6
IMPlications of IMP2 in RNA Biology and Disease
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062415 · Cited by 3
“Through ELISA, IMP2 has been shown to trigger an autoimmune response in breast cancer, as evidenced by the presence of autoantibodies [99], suggesting the potential of screening for IMP2 as a biomarker for breast cancer.”
Metadata
- Authors
- Liu, W., Li, Y., Wang, B., Dai, L., Qian, W., & Zhang, J. ‐.
- Venue
- Scandinavian Journal of Immunology
- Publisher
- Wiley
- Published
- 2015-05-13
- Volume
- 81
- Issue
- 6
- Pages
- 502-507
- ISSN
- 0300-9475 (ISSN-L)
- 1365-3083
- OpenAlex
- W2153749689
- Cited by
- 37
- References
- 1
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- National Institutes of Health (SC1CA166016)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoimmune Response to IGF 2 mRNA‐Binding Protein 2 (IMP 2/p62) in Breast Cancer. https://app.cochat.ai/papers/10.1111/sji.12285
- The paper
- Liu, W., Li, Y., Wang, B., Dai, L., Qian, W., & Zhang, J. ‐. (2015). Autoimmune Response to IGF 2 mRNA‐Binding Protein 2 (IMP 2/p62) in Breast Cancer. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.12285
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.